Resmed (RMD, Financial) has appointed Salli Schwartz as its Chief Investor Relations Officer, with the role taking effect on April 21. In this position, Schwartz will oversee the company's global investor relations strategies and initiatives, directly reporting to CEO Mick Farrell.
Schwartz brings extensive experience to Resmed, having previously led the investor relations team at Illumina. Her expertise is expected to enhance Resmed's communication with the investment community and support its growth objectives.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for ResMed Inc (RMD, Financial) is $263.95 with a high estimate of $295.00 and a low estimate of $195.00. The average target implies an upside of 25.17% from the current price of $210.87. More detailed estimate data can be found on the ResMed Inc (RMD) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, ResMed Inc's (RMD, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ResMed Inc (RMD, Financial) in one year is $287.86, suggesting a upside of 36.51% from the current price of $210.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ResMed Inc (RMD) Summary page.
